{"id":"NCT02924064","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09","primaryCompletion":"2018-09-25","completion":null,"firstPosted":"2016-10-05","resultsPosted":"2022-01-28","lastUpdate":"2022-03-09"},"enrollment":247,"design":{"allocation":null,"model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin 20mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin â‰¥ 1000 mg","otherNames":[]}],"arms":[{"label":"Teneligliptin 20mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with metformin.","primaryOutcome":{"measure":"The Changes in HbA1c at Week 24","timeFrame":"at Day 1(baseline) and Week 24","effectByArm":[{"arm":"Teneligliptin 20mg + Metformin","deltaMin":-0.72,"sd":0.07},{"arm":"Placebo + Metformin","deltaMin":-0.01,"sd":0.07}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":124},"commonTop":["Upper respiratory tract infection","Hyperuricaemia","Hyperlipidaemia","Proteinuria","Hypertension"]}}